Kernal Biologics
YC S20 · Active · Kernal is creating mRNA 2.0 therapies that work in specific cells
Competitors
| Company | Category | Status | Program |
|---|---|---|---|
 Asher BioShared: biotech, cell, targetedActiveOther | Other | Active | YCS19 |
 Altay TherapeuticsShared: approved therapy, fda approved, biotechActiveAI | AI | Active | YCW20 |
 Entelexo BiotherapeuticsShared: autoimmune disease, biotech, creatingActiveOther | Other | Active | YCW21 |
 ParcelBioShared: autoimmune disease, biotech, mrnaActiveOther | Other | Active | YCW24 |
 Sigma GeneticsShared: genomics, biotech, cellActiveOther | Other | Active | YCW17 |
Adjacent
| Company | Category | Status | Program |
|---|---|---|---|
 Epana BioShared: autoimmune disease, therapy, precisionNot statedOther | Other | Not stated | SPC2025 |
 Sensible BiotechnologiesShared: biotech, mrna, cellActiveOther | Other | Active | YCS21 |
 SFA TherapeuticsShared: autoimmune disease, biotech, creatingActiveAI | AI | Active | YCS21 |
 Ochre BioShared: genomics, biotech, diseaseActiveOther | Other | Active | YC +1W20 |
 Helix NanotechnologiesShared: genomics, biotech, mrnaActiveAI | AI | Active | YCW17 |
Also from S20 in AI
All of S20
About Kernal Biologics
Kernal Bio is a biotech company pioneering mRNA 2.0 immunotherapies. We leverage selective mRNA-LNP technology to treat cancer and autoimmune diseases with precision, ensuring targeted cell delivery and minimal off-target effects. Our KR-402 program achieves over 90% delivery efficiency with T-cell-targeted LNPs, enabling direct CAR-T programming within the body and resulting in B-cell depletion within a week. Kernal Bio is led by a team with experience from MIT, Harvard, Merck, and BMS, boasting three FDA-approved therapies and over 120 patents. Based in Cambridge, MA, we are backed by Hummingbird Ventures, Amgen Ventures, HBM, and even NASA. With roots at MIT, Harvard and Biopharma, Kernal’s management team has deep expertise in mRNA therapeutics space. CEO Yusuf Erkul, M.D., M.B.A. is a successful drug hunter whose research at Merck enabled an FDA-approved drug for ovarian cancer. President Burak Yilmaz, M.S., previously founded Sentegen, a thriving synthetic biology company which commercializes synthetic DNA, RNA, and diagnostic kits for genetic and infectious diseases. Sr. VP of R&D Manfred Kraus is a leader in immuno-oncology, who was most recently Scientific Sr. Director at Bristol-Myers Squibb (BMS).
- YC batch
- S20 · Summer 2020
- Status, per YC
- Active
- Category
- AI
- Team size
- 20
- Location
- Boston, MA, USA
- Checked
- 36m ago
YC tags: Artificial Intelligence, Biotech, Genomics
Kernal Biologics: questions
Which YC batch was Kernal Biologics in?
Kernal Biologics was in Y Combinator's Summer 2020 batch (S20).
Is Kernal Biologics still active?
Y Combinator lists Kernal Biologics as active.
Where is Kernal Biologics based?
Kernal Biologics lists Boston, MA, USA as its location on YC's directory.
Sources: each program's public company list, read twice a week. Not affiliated with Y Combinator or any other program. Logos via logo.dev; trademarks belong to their owners.